AzTrials
AzTrials

Advanced Malignant Solid NeoplasmPhase 1NCT05653661

Nab-Paclitaxel/STI-3031 Complex (AP160-Complex) for the Treatment of Advanced or Metastatic Solid Tumors

A Phase 1 study testing Biopsy, Biospecimen Collection and Computed Tomography in people with Advanced Malignant Solid Neoplasm and Metastatic Malignant Solid Neoplasm, run by Mayo Clinic at 1 site in United States.

Withdrawn

Withdrawn. The study stopped before anyone enrolled.

Official record
Search all trials

Trial summary

This phase I trial tests the safety, side effects, and best dose of a new drug called nab-paclitaxel/STI-3031 complex (AP160-complex) in treating patients with solid tumors that may have spread from where they first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that have spread from… Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Biopsy, Biospecimen Collection and Computed Tomography
Could I receive a placebo?
No, everyone receives an active treatment
How many people
0 participants
Where
1 siteUnited States
Study dates
30 Jul 2024to 30 Jul 2024
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Provide written informed consent
  • PRE-REGISTRATION
  • Age >= 18 years
  • Willingness to provide mandatory pre-registration tissue specimen for research
  • At least one prior systemic therapy in the metastatic setting (adjuvant or neoadjuvant therapy not included).
  • NOTE: There is no upper limit to the number of prior treatment regimens
Show all 35Show fewer
  • Dose Escalation Cohort Only
  • Patients with histologically or cytologically confirmed advanced or metastatic non-neurological solid tumors, who have no curative or life prolonging therapeutic options
  • Melanoma Dose Expansion Cohort Only
  • Histologic proof of surgically unresectable stage IV malignant melanoma
  • Disease progression on or after anti-PD1/PDL1 antibody-based therapy in the metastatic setting (adjuvant or neoadjuvant therapy with anti-PD1/PDL1 antibody do not count)
  • REGISTRATION
  • Tissue submitted for testing at pre-registration shows minimal level of tumor staining for PDL1 (clinical test using 22c3 immunohistochemistry) demonstrating tumor staining in >= 1% of tumor cells
  • Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0, 1 or 2
  • Hemoglobin >= 9.0 g/dL (patients may be transfused to meet hemoglobin [Hgb] requirement) (obtained =< 14 days prior to registration)
  • Absolute neutrophil count (ANC) >= 1500/mm^3 (obtained =< 14 days prior to registration)
  • Platelet count >= 100,000/mm^3 (obtained =< 14 days prior to registration)
  • Total bilirubin =< 1.5 x upper limit of normal (ULN) or direct bilirubin =< 0.4 mg/dL (obtained =< 14 days prior to registration)
  • Serum glutamic-oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) =< 2.5 x ULN or =< 5 x ULN in case of liver metastases (obtained =< 14 days prior to registration)
  • Alkaline phosphatase =< 2.5 x ULN or =< 5 x ULN in case of liver metastases (obtained =< 14 days prior to registration)
  • Calculated creatinine =< 1.5 x ULN or calculated creatinine clearance >= 45 ml/min using the Cockcroft-Gault formula for subjects with creatinine > 1.5 ULN (obtained =< 14 days prior to registration)
  • Negative serum pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
  • No motor peripheral neuropathy
  • Sensory peripheral neuropathy =< Grade 1 (per Common Terminology Criteria for Adverse Events [CTCAE] 5.0)
  • Immune-related adverse events (irAEs) from prior treatment have returned to baseline or =< Grade 1
  • For persons of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use a contraceptive method with a failure rate of < 1% per year during the treatment period and for 6 months after the last dose of study treatment
  • For person able to father a child: agreement to remain abstinent (refrain from heterosexual intercourse with a person of childbearing potential) or use contraceptive measures, and agreement to refrain from donating sperm during the treatment period and for 6 months after the last dose of study treatment
  • Willingness to provide mandatory blood specimens for correlative research
  • Willingness to provide mandatory tissue specimens for correlative research
  • Willing to return to enrolling institution for follow-up 2-4 weeks after treatment discontinuation
  • Life expectancy >= 90 days (3 months)
  • Dose Expansion Cohorts Only
  • NOTE: Melanoma Dose Expansion cohort only planned for now. Availability to add other disease-specific dose expansion cohorts possible in future protocol amendments.
  • Measurable disease defined as at least one lesion whose longest diameter can be accurately measured as >= 1.0cm with computed tomography (CT) scan or magnetic resonance imaging (MRI) scan; or CT component of a positron emission tomography (PET)/CT.
  • NOTE: Disease that is measurable by physical examination only is not eligible

Who cannot join

  • Any of the following because this study involves an investigational agent whose genotoxic, mutagenic, and teratogenic effects on the developing fetus and newborn are unknown:
  • Pregnant persons
  • Nursing persons
  • Persons of childbearing potential {and persons able to father a child} who are unwilling to employ adequate contraception
  • Known standard therapy for the patient's disease that is potentially curative or definitely capable of extending life expectancy
  • Any anti-cancer therapy or investigational agents =< 4 weeks prior to registration
Show all 48Show fewer
  • Failure to recover from prior surgery
  • Failure to fully recover from acute, reversible effect of prior chemotherapy regardless of interval since last treatment
  • Anti-PD(L)1 antibody =< 4 weeks prior to registration
  • Previous grade 4 irAEs from immune checkpoint inhibitor antibody therapy
  • Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
  • Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy
  • NOTE: Patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial
  • Uncontrolled intercurrent illness including, but not limited to:
  • ongoing or active infection
  • symptomatic congestive heart failure
  • unstable angina pectoris
  • cardiac arrhythmia
  • or psychiatric illness/social situations that would limit compliance with study requirements
  • Other medical conditions including be not limited to:
  • History of liver disease such as cirrhosis, chronic active hepatitis, chronic persistent hepatitis or hepatitis B or C.
  • Active infection requiring parenteral antibiotics
  • Active tuberculosis or active, non-infectious pneumonitis
  • Evidence of interstitial lung disease
  • New York Heart Association class II-IV congestive heart failure (Serious cardiac arrhythmia requiring medication)
  • Myocardial infarction or unstable angina =< 6 months prior to registration
  • Congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias
  • Active autoimmune disease such as Crohn's disease, rheumatoid arthritis, Sjogren's disease, systemic lupus erythematosus, or similar conditions requiring systemic therapy within the past 2 years with the use of disease modifying agents, corticosteroids, or immunosuppressants or a documented history of clinically severe autoimmune disease/syndrome difficult to control in the past
  • EXCEPTIONS (the following are allowed):
  • Vitiligo or resolved childhood asthma/atopy
  • Intermittent use of bronchodilators or local steroid injections
  • Non-immunosuppressive maintenance treatments in the setting of clinically asymptomatic disease (e.g., sulfasalazine for ulcerative colitis)
  • Hypothyroidism or hypoadrenalism, stable on hormone replacement,
  • Diabetes stable with current management
  • History of positive Coombs's test but no evidence of hemolysis
  • Psoriasis not requiring systemic treatment
  • Conditions not expected to recur in the absence of an external trigger
  • Secondary adrenal insufficiency from previous hypophysitis, currently on physiologic replacement steroid dosing only
  • Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
  • Other active malignancy =< 3 years prior to registration. Patients must not be receiving chemotherapy or immunotherapy for another cancer. Patients must not have another active malignancy requiring active treatment
  • EXCEPTIONS: Non-melanotic skin cancer or carcinoma-in-situ of the cervix
  • NOTE: If there is a history of prior malignancy, they must not be receiving other specific treatment
  • NOTE: Early-stage cancer (stage 1/2, treated) should be allowed
  • History of myocardial infarction =< 6 months, or congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias
  • Active central nervous system (CNS) metastasis
  • NOTE: Patients with prior brain metastases that are asymptomatic without corticosteroid use and stable or improved >= 30 days after treatment with surgery or radiation are not excluded
  • Corticosteroid use =< 14 days prior to registration. NOTE: Patients must be off systemic corticosteroids for at least 2 weeks prior to registration. This includes oral or IV route of administration. Patients on chronic corticosteroids for adrenal insufficiency or other reasons may enroll if they receive less than 10 mg/day of prednisone (or equivalent). Patients receiving inhaled or intranasal or intraarticular steroids are not excluded
  • EXCEPTIONS: Patients requiring steroid premedication for radiology contrast allergy are not excluded

Trial locations and contacts

1 site in 1 country.

United States1 site

  • Mayo Clinic in Rochester

    Rochester, Minnesota, 55905

Other trials in United States

About this study

Official title: A Phase I Study of Nab-Paclitaxel/STI-3031 Complex (AP160-Complex) in Patients with Advanced Solid Tumors

This phase I trial tests the safety, side effects, and best dose of a new drug called nab-paclitaxel/STI-3031 complex (AP160-complex) in treating patients with solid tumors that may have spread from where they first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that have spread from where they first started (primary site) to other distant parts of the body (metastatic). AP160-complex is a combination of the chemotherapy drug nab-paclitaxel, and the immunotherapy drug STI-3031. Nab-paclitaxel is in a class of medications called antimicrotubule agents. It works by stopping the growth and spread of tumor cells. Immunotherapy with monoclonal antibodies, such as STI-3031, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. AP160-complex may work better than standard therapies in treating advanced or metastatic solid tumors.

Read the detailed description

PRIMARY OBJECTIVE:

  1. To determine the maximum tolerated dose (MTD) and/or the recommended phase 2 dose (RP2D) for nab-paclitaxel/danburstotug complex AP160 (AP160).

SECONDARY OBJECTIVES:

  1. To determine the toxicity profile of AP160 when administered as an intravenous (IV) infusion.

II. To determine the best response with AP160.

CORRELATIVE RESEARCH OBJECTIVES:

  1. To assess the evidence of immune response. II. To characterize the pharmacokinetics of paclitaxel administered in the context of AP160-complex.

III. To assess the tumor concentrations of paclitaxel 24 hours (h) following AP160-complex infusion and correlation with plasma levels.

IV. To assess the antitumor activity of the recommended phase II dose of AP160 in patients with metastatic solid tumors.

OUTLINE: This is a phase I, dose-escalation study followed by a dose-expansion study.

Patients receive AP160-complex IV on study. Patients in the dose-escalation cohort undergo computed tomography/magnetic resonance imaging (MRI) scans, tissue biopsies, and collection of blood samples throughout the trial. Patients in the dose-expansion cohort undergo MRI scan during screening, collection of blood samples during screening and on study, and tissue biopsies throughout the trial.

Being tested
Biopsy, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Nab-paclitaxel/Danburstotug Complex AP160
Medical subject headings
Neoplasm Metastasis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • BiopsyProcedure or surgery

    Also called BIOPSY_TYPE, Bx

    Undergo tissue biopsies

  • Biospecimen CollectionProcedure or surgery

    Also called Biological Sample Collection, Biospecimen Collected, Specimen Collection

    Undergo collection of blood samples

  • Computed TomographyProcedure or surgery

    Also called CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography

    Undergo CT scans

  • Magnetic Resonance ImagingProcedure or surgery

    Also called Magnetic Resonance, Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR

    Undergo MRI scans

  • Nab-paclitaxel/Danburstotug Complex AP160Drug

    Also called AP 160, AP-160, AP160, Nab-paclitaxel/STI-3031 Complex AP160

    Given IV

Study groups in NCT05653661
Study groupRoleWhat they receive
Treatment (AP160-complex)ExperimentalPatients receive AP160-complex IV on study. Patients in the dose-escalation cohort undergo computed tomography/magnetic resonance imaging (MRI) scans, tissue biopsies, and collection of blood samples throughout the trial. Patients in the dose-expansion cohort undergo MRI scan during screening, collection of blood samples during screening and on study, and tissue biopsies throughout the trial.
Receives: Procedure: Biopsy; Procedure: Biospecimen Collection; Procedure: Computed Tomography; Procedure: Magnetic Resonance Imaging; Drug: Nab-paclitaxel/Danburstotug Complex AP160

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Maximally tolerated dose (MTD)

    MTD is defined as the dose level below the lowest dose that induces dose-limiting toxicity (DLT) in at least one-third of patients (at least 2 of a maximum of 6 new patients).

    Measured: Up to 28 days (Cycle 1)

Secondary outcomes (2)

  1. Incidence of adverse events

    Overall toxicity incidence as well as toxicity profiles by dose level, patient and tumor site will be explored and summarized. Frequency distributions, graphical techniques and other descriptive measures will form the basis of these analyses.

    Measured: Up to 90 days after last dose of AP160-complex

  2. Best response

    The patient's best response assignment will depend on the achievement of both measurement and confirmation criteria. The modified Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria will be used for tumor evaluation and patients will be re-evaluated every 8 weeks. Responses will be summarized by simple descriptive summary statistics delineating complete and partial responses as well as stable and progressive disease in this patient population (overall and by tumor group). The number of responses may indicate further evaluation for specific tumor types in a Phase II setting.

    Measured: From the start of the treatment until disease progression/recurrence, assessed up to 2 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 Dec 2022
  2. Study start30 Jul 2024
  3. Primary completion30 Jul 2024
  4. Study completion30 Jul 2024

Why it stopped: Sponsor business considerations

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
0 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05653661
Sponsor's protocol ID
MC210104
Other IDs
NCI-2022-09248, 22-000906
Status last verified
Jan 2025
First submitted
8 Dec 2022
Last updated
7 Jan 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing Biopsy, Biospecimen Collection and Computed Tomography in people with Advanced Malignant Solid Neoplasm and Metastatic Malignant Solid Neoplasm, run by Mayo Clinic at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 35 inclusion and 48 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: withdrawn, as of the sponsor's last update on 7 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study was withdrawn before enrolling participants, so there are no results.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Maximally tolerated dose (MTD) (time frame: Up to 28 days (Cycle 1)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05653661.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Jan 2025.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in